APA (7th ed.) Citation

DH, A., M, R., TL, C., L, M., JS, S., JM, H., . . . HJ, L. (2025). Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(7), 840. https://doi.org/10.1200/JCO-24-01266

Chicago Style (17th ed.) Citation

DH, Ahn, et al. "Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 7 (2025): 840. https://doi.org/10.1200/JCO-24-01266.

MLA (9th ed.) Citation

DH, Ahn, et al. "Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 7, 2025, p. 840, https://doi.org/10.1200/JCO-24-01266.